Incidence and Characterization of Concealed Cardiac Amyloidosis Among Unselected Elderly Patients Undergoing Post-mortem Examination.
Dr Silvia OGHINA : Cardiologue APHP Henri Mondor – Créteil Incidence and Characterization of Concealed Cardiac Amyloidosis Among Unselected Elderly Patients Undergoing Post-mortem Examination. https://pubmed.ncbi.nlm.nih.gov/34888361/
Prevalence and determinants of iron deficiency in cardiac amyloidosis.
Dr Benoît LEQUEUX : Cardiologue CHU de Poitiers Prevalence and determinants of iron deficiency in cardiac amyloidosis. https://pubmed.ncbi.nlm.nih.gov/35128833/. PMID : 35128833
Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Pr François TOURNOUX : Cardiologue – CHU de Montréal CANADA Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS). https://pubmed.ncbi.nlm.nih.gov/35451899/ PMID : 35451899
Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression.
Dr Eve CARIOU – Cardiologue CHU de Toulouse Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression. https://pubmed.ncbi.nlm.nih.gov/33129740/ PMID : 33129740
Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT])
Dr Zoubida TAZI MEZALEK – Cardiologue CHU de Rabat MAROC Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]) https://pubmed.ncbi.nlm.nih.gov/33667442/ PMID : 33667442
Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis.
Dr Martin NICOL : Cardiologue APHP Lariboisière – Paris https://pubmed.ncbi.nlm.nih.gov/35292807/ PMID : 35292807
Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
Dr Clément BECLE Cardiologique – Centre Cardiologique de l’Ouest Lyonnais – Lyon https://pubmed.ncbi.nlm.nih.gov/33220323/ PMID : 33220323
ST‑elevation myocardial infarction among cardiac amyloidosis patients; a national readmission database study
Pr François ROUBILLE : Cardiologue resp. équipe médicale insuffisance cardiaque – CHU de Montpellier ST‑elevation myocardial infarction among cardiac amyloidosis patients; a national readmission database study. https://pubmed.ncbi.nlm.nih.gov/35048207/ PMID : 35048207
Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis
Dr Damien EYHARTS : Cardiologue CHU de Toulouse Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis https://pubmed.ncbi.nlm.nih.gov/35178887/ PMID : 35178887
Utilization and tolerance of beta-blockers among patients with AL amyloidosis.
Jean-Jacques VON HUNOLSTEIN : Cardiologue Hopital Civil STRASBOURG Utilization and tolerance of beta-blockers among patients with AL amyloidosis. https://pubmed.ncbi.nlm.nih.gov/34549676/ PMID : 34549676
